OraSure Technologies (NASDAQ:OSUR) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a strong sell rating in a report published on Thursday, September 20th.

A number of other equities research analysts have also commented on the company. TheStreet upgraded OraSure Technologies from a c+ rating to a b rating in a research report on Thursday, August 9th. Zacks Investment Research lowered OraSure Technologies from a buy rating to a hold rating in a research report on Tuesday, August 7th. Stephens lowered OraSure Technologies from an overweight rating to an equal weight rating in a research report on Monday, July 16th. Finally, ValuEngine upgraded OraSure Technologies from a hold rating to a buy rating in a research report on Friday, July 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. OraSure Technologies currently has a consensus rating of Hold and a consensus target price of $21.33.

OSUR stock traded up $0.03 during midday trading on Thursday, reaching $14.24. 446,148 shares of the stock were exchanged, compared to its average volume of 536,088. The firm has a market capitalization of $945.13 million, a P/E ratio of 27.92, a P/E/G ratio of 3.43 and a beta of 1.53. OraSure Technologies has a 52 week low of $12.86 and a 52 week high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, August 8th. The medical instruments supplier reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. The business had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. OraSure Technologies had a return on equity of 5.85% and a net margin of 8.38%. OraSure Technologies’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 EPS. On average, sell-side analysts anticipate that OraSure Technologies will post 0.36 earnings per share for the current fiscal year.

In related news, Director Charles W. Patrick sold 8,000 shares of the company’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $16.29, for a total transaction of $130,320.00. Following the sale, the director now owns 54,298 shares in the company, valued at approximately $884,514.42. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.90% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its stake in OraSure Technologies by 3.3% during the 1st quarter. Principal Financial Group Inc. now owns 491,188 shares of the medical instruments supplier’s stock worth $8,296,000 after buying an additional 15,717 shares during the period. Macquarie Group Ltd. raised its stake in OraSure Technologies by 17.5% during the 2nd quarter. Macquarie Group Ltd. now owns 93,701 shares of the medical instruments supplier’s stock worth $1,543,000 after buying an additional 13,986 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in OraSure Technologies by 196.4% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 49,063 shares of the medical instruments supplier’s stock worth $808,000 after buying an additional 32,511 shares during the period. Cubist Systematic Strategies LLC acquired a new position in OraSure Technologies during the 1st quarter worth approximately $139,000. Finally, Emerald Advisers Inc. PA raised its stake in OraSure Technologies by 49.1% during the 2nd quarter. Emerald Advisers Inc. PA now owns 1,007,294 shares of the medical instruments supplier’s stock worth $16,590,000 after buying an additional 331,922 shares during the period. Institutional investors own 91.76% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Recommended Story: Stock Split

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.